QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 专题：中南大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文 The Patient - Patient-Centered Outcomes Research, 2018, 卷号: 11, 期号: 1, 页码: 131-141 作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells 期刊论文 Cell Death & Disease, 2018, 卷号: 9, 期号: 3, 页码: 322 作者:  Liu, Jing;  Livingston, Man J.;  Dong, Guie;  Tang, Chengyuan;  Su, Yunchao 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/03 EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 期刊论文 British Journal of Cancer, 2017, 卷号: 116, 期号: 2, 页码: 175-185 作者:  Wu, Yi-Long*;  Sequist, Lecia V;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 EGFR mutation  ERBB family blocker  afatinib  circulating cell-free DNA  non-small cell lung cancer   Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma 期刊论文 Oncotarget, 2016, 卷号: 7, 期号: 42, 页码: 68585-68596 作者:  Li, Yunchao;  Zhao, Chunhua;  Yu, Zhibin;  Chen, Jiarui;  She, Xiaoling 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 miR-381  osteosarcoma  LRRC4  chemosensitivity   Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. 期刊论文 Journal of Thoracic Oncology, 2015, 卷号: 10, 期号: 6, 页码: 883-889 作者:  Geater, Sarayut L;  Xu, Chong-Rui;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 Afatinib  Non-small-cell lung cancer  Patient-reported outcomes  Progression-free survival  Quality of life   Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials 期刊论文 The Lancet Oncology, 2015, 卷号: 16, 期号: 2, 页码: 141-151 作者:  Yang, James Chih-Hsin*;  Wu, Yi-Long;  Schuler, Martin;  Sebastian, Martin;  Popat, Sanjay 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/03 Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial 期刊论文 The Lancet Oncology, 2014, 卷号: 15, 期号: 2, 页码: 213-222 作者:  Wu, Yi-Long*;  Zhou, Caicun;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/03